<DOC>
	<DOCNO>NCT01138605</DOCNO>
	<brief_summary>The primary objective study continue provide Darunavir ( DRV ) pediatric patient previously receive DRV three pediatric clinical study sponsor Tibotec Pharmaceuticals continue benefit use , country DRV yet commercially available pediatric patient , reimburse access another source ( like access program government program ) .</brief_summary>
	<brief_title>TMC114-TiDP29-C232 - Study Providing Continued Access Treatment With Darunavir ( DRV ) /Ritonavir ( Rtv ) Children Coming From Any Three Ongoing Tibotec Sponsored Pediatric Studies With DRV</brief_title>
	<detailed_description>This study aim continue provision DRV rtv pediatric patient continue benefit treatment participation three ongoing pediatric study sponsor Tibotec Pharmaceuticals . In addition , information safety DRV rtv combination antiretroviral therapy assess . At baseline visit , inclusion exclusion criterion check confirm eligibility . Once eligible , patient continue treatment either daily dose regimen ( come TMC114-TiDP29-C230 study ) twice daily regimen ( come TMC114-C212 TMC114-TiDP29-C228 study ) . Assessments visit frequency take place per local standard care desirable every 3 month . The interval two visit exceed 6 month . Pregnancy test girl first menses foreseen . In addition , desirable test include efficacy assessment ( immunology plasma viral load ) laboratory safety assessment ( hematology , biochemistry include pancreatic amylase ( available ) lipase lipid analysis ) . Serious Adverse Events certain selected Adverse Events collect . Treatment continue one follow criterion meet ( whichever occurs first ) : Virologic failure , treatment limit toxicity , loss follow-up , withdrawal consent assent patient withdrawal consent caregiver , pregnancy , termination trial sponsor , Darunavir become commercially available , reimburse access another source ( access program government program ) region patient living . The sponsor advise participate center plan study visit every 3 month frequency depend local practice standard care . The sponsor also foreseen study protocol guidance specific safety assessment perform well detailed instruction deal specific toxicity undesirable effect . However local practice prevail assessment perform may vary depend region patient participate . Intake study medication happen daily twice daily , depend patient take original pediatric trial . For twice daily regimen , regimen may adjust patient gain weight . The adult dosage regimen 600/100 mg DRV/rtv may administer 40 kg body weight . Depending history patient , follow dosage may administer : DRV oral suspension ( 100mg DRV/ml ) , DRV tablets 75 mg , 150 mg , 600 mg , twice daily intake . DRV 400 mg daily 800 mg intake ( 2 tablet per intake ) .DRV intake combine rtv oral suspension ( 80 mg rtv/ml ) , capsule tablet ( 100 mg ) .</detailed_description>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Patient complete TMC114C212 , TMC114TiDP29C228 TMC114TiDP29C230 study continue benefit DRV DRV commercially available , reimburse access another way sign informed consent parents/caregivers assent patient available prior inclusion Any condition active clinically significant disease ( pancreas problem cardiac problem ) endanger patient safety enrol study Previously demonstrate clinically significant allergy hypersensitivity study medication Pregnancy breastfeed female patient Specific criterion applicable girl first menses girl boy reach age sexual activity</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>TMC114</keyword>
	<keyword>TMC114-TiDP29-C232</keyword>
	<keyword>TMC114-C232</keyword>
	<keyword>Darunavir</keyword>
	<keyword>PREZISTA</keyword>
</DOC>